References
- Keating M J, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755–1762
- Osterborg A, Dyer M J, Bunjes D, Pangalis G A, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567–1574
- Keating M J, Flinn I, Jain V, Binnet J L, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561
- Rai K R, Freter C E, Mercier R J, Cooper M R, Mitchell B S, Stadtmauer E A, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891–3897
- Faderl S, Coutrè C, Byrd J C, Dearden C, Denes A, Dyer M JS, et al. The evolving role of alemtuzumab in management of patients with CLL. Leukemia 2005; 19: 2147–2152
- O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008; 111: 1816–1819
- Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiuslo P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004; 89: 1248–1252
- Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 2337–2342
- Smolej L. Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice. Blood 2008; 112: 2167
- Visani G, Mele A, Guiducci B, D'Adamo F, Leopardi G, Barulli S, et al. An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. Leuk Lymphoma 2006; 47: 2542–2546